Barry Greenberg, PhD

Director, Neuroscience Drug Discovery and Development, University Health Network Director of Strategy, Toronto Dementia Research Alliance Toronto Western Research Institute

Barry Greenberg has been involved in Alzheimer’s disease research and drug discovery since 1985. He has held a series of positions internationally in the US, Sweden and Canada within the biotechnology and pharmaceutical industries. Dr. Greenberg was the leader of a drug discovery project at AstraZeneca through lead optimization, involving up to 50 individuals from eight departments. Before joining UHN as Director, Neuroscience Drug Discovery and Development, he was Senior Director of Pharmacology at Neurochem, responsible for the preclinical biology research program and a contributor to the analyses of the phase III Alzhemed trial. At UHN, he is also Strategy Director of the Toronto Dementia Research Alliance, a consortium involving academic research and the five memory clinics at hospitals affiliated with the University of Toronto to create a citywide dementia research center. He possesses a significant background in most aspects of the drug discovery process in neurological disease, with externally recognized expertise ranging from target identification and validation through preclinical and clinical development including issues of biomarker-based diagnosis and proof of concept. He has a strong international network in the Alzheimer field including industry, academia, government and the voluntary sector, plus previous involvement in multi-sector consortia. Dr. Greenberg was a member of the committee charged with drafting the scientific strategic recommendations to inform the National Alzheimer Plan in the US in 2012, and was appointed as Chair of the Executive-Writing Committee for the follow-up Alzheimer Research Summit at the NIA in February 2015. He has authored or co-authored 70 articles in peer-reviewed journals and 19 book chapters and reviews.